Australian startups secure $15.6M for dementia tech

• Seven early-stage Australian health startups secured a combined $15.6 million in non-dilutive government grants.
• Individual allocations range between $1.6 million and $2.5 million per startup without equity dilution.
• The capital aims to accelerate commercialisation of novel dementia diagnostics, treatments, and digital tools.

Seven Australian startups have secured $15.6 million in non-dilutive federal funding to commercialise dementia diagnostics, therapies, and digital tools.

The capital injection comes via the second round of the CUREator+ Dementia & Cognitive Decline programme, which is backed by the Medical Research Future Fund.

"Dementia will require multiple approaches, from earlier detection through to treatments that can slow or alter disease progression," said CUREator Programme Head Amanda Vrselja.

Under the allocation, Kinoxis Therapeutics and TasTest received $2.5 million, Synerva Therapeutics took $2.5 million, Quithera secured $2.4 million, CodeBreakers drew $2.1 million, Healthily collected $1.9 million and Intracellica Bio gained $1.6 million.

The programme pairs non-dilutive grants with industry mentorship to transform early-stage research into investable healthcare businesses capable of securing private follow-on capital.

The funded projects focus on various health tools, including gene-editing therapies for childhood dementia, AI voice tools for detecting cognitive decline, and digital risk self-assessments.